Peptides and Fertility: What Men and Women Need to Know

The intersection of peptides and fertility is complex because different peptide classes affect the reproductive axis at different levels — some supportive, some neutral, some potentially harmful. Anyone using peptides while planning conception needs to understand these distinctions.

Peptides that support fertility

Kisspeptin

Kisspeptin is endogenous to the reproductive axis — it's the upstream trigger for GnRH pulsatility, which drives LH, FSH, and ultimately gonadal function. Research into kisspeptin for fertility is among the most active areas in reproductive endocrinology:

In women:

• Kisspeptin-54 (the full-length form) has been studied as an alternative to hCG for triggering ovulation in IVF cycles, with potential for lower OHSS (ovarian hyperstimulation syndrome) risk
• Clinical trials (Abbara et al., 2015, 2017) showed kisspeptin triggers oocyte maturation with significantly less ovarian hyperstimulation than conventional hCG triggers
• Research into kisspeptin for hypothalamic amenorrhea (functional loss of menstrual cycles from stress, low body weight, or excessive exercise) shows promising LH restoration

In men:

• Acute kisspeptin administration produces robust LH and testosterone responses
• May be useful for men with hypothalamic hypogonadism who want to maintain fertility (TRT suppresses spermatogenesis; kisspeptin does not)
• Research is ongoing for male infertility associated with HPG axis dysfunction

Gonadorelin

Synthetic GnRH identical to the endogenous 10-amino-acid peptide. Used clinically in fertility medicine:

• Pulsatile gonadorelin therapy can restore ovulation in women with hypothalamic amenorrhea
• In men, pulsatile GnRH can restore spermatogenesis and testosterone production in hypothalamic hypogonadism
• Some clinics prescribe gonadorelin alongside TRT to maintain testicular function and fertility

Critical nuance: Pulsatile delivery supports fertility; continuous delivery suppresses it (the mechanism used by GnRH agonists like leuprolide in prostate cancer and endometriosis).

Peptides with fertility implications

GLP-1 Receptor Agonists (semaglutide, tirzepatide)

The "Ozempic babies" phenomenon has generated significant attention. Several mechanisms may explain improved fertility on GLP-1 therapy:

In women with PCOS:

• Weight loss improves ovulatory function — many anovulatory women with PCOS resume spontaneous ovulation after 5–10% weight loss
• GLP-1 agonists reduce insulin resistance, which is a driver of hyperandrogenism in PCOS
• Some evidence for direct ovarian GLP-1 receptor effects, though this is early-stage research
• Semaglutide and tirzepatide are not approved for use during pregnancy and should be discontinued at least 2 months before planned conception (semaglutide) due to embryo-fetal toxicity in animal studies

In men:

• Weight loss increases testosterone (reduced aromatase activity in adipose tissue)
• Improved insulin sensitivity may support Leydig cell function
• No direct negative effect on spermatogenesis has been identified in clinical trials, but data is limited

Important: The FDA recommends discontinuing semaglutide at least 2 months before planned pregnancy, and tirzepatide at least 1 month before. Animal studies showed embryo-fetal toxicity at clinical doses. This is a risk that cannot be dismissed.

GH Secretagogues (CJC-1295, ipamorelin, sermorelin)

GHS peptides influence reproductive function indirectly through GH/IGF-1:

• GH plays a supportive role in follicular development and oocyte quality in women
• IGF-1 supports Sertoli cell function and spermatogenesis in men
• GH co-treatment has been studied as an adjunct in poor-responder IVF patients, with mixed but generally positive results

Concern: Supraphysiological IGF-1 levels could theoretically interfere with embryo implantation or early development. There is no clinical data on GHS peptide use during conception attempts, so a precautionary approach is warranted.

Melanotan II and PT-141

• Melanotan II has been associated with priapism in case reports, which while not a direct fertility issue, indicates potent effects on reproductive physiology
• No data on effects on spermatogenesis or oocyte quality
• The melanocortin system has roles in reproductive behavior and physiology, but the implications for fertility are unknown
• Precautionary discontinuation before conception is reasonable

Peptides to avoid when trying to conceive

BPC-157 and TB-500

No reproductive toxicity data exists for either peptide. The precautionary principle applies — in the absence of safety data:

• Animal studies have not specifically evaluated reproductive outcomes
• Pro-angiogenic mechanisms (particularly VEGFR2 for BPC-157) could theoretically affect implantation and early placental development in ways that are completely unstudied
• Discontinue before planned conception until safety data exists

Any peptide without reproductive safety data

The default for any research peptide without reproductive toxicology studies should be discontinuation before conception — for both partners. Spermatogenesis takes approximately 74 days, so men should ideally discontinue research peptides at least 3 months before planned conception.

Practical timeline for conception planning

For women:

1. 3+ months before conception: Discontinue all research peptides (BPC-157, TB-500, Melanotan II, etc.)
2. 2+ months before: Discontinue semaglutide (per FDA guidance)
3. 1+ month before: Discontinue tirzepatide (per FDA guidance)
4. Continue if appropriate: Prenatal supplements, kisspeptin or gonadorelin only under specialist supervision
5. During pregnancy: No research peptides. Only FDA-approved medications under obstetric supervision

For men:

1. 3+ months before conception: Discontinue research peptides and any peptides without reproductive safety data (covers one full spermatogenesis cycle)
2. Consider continuing: GHS peptides at moderate doses with IGF-1 monitoring (supportive of testosterone/spermatogenesis, but precautionary discontinuation is also reasonable)
3. Key point: If on TRT, adding gonadorelin or hCG to maintain spermatogenesis, or transitioning off TRT with PCT support — discuss with reproductive endocrinologist

The bottom line

Peptides sit on a spectrum from fertility-supportive (kisspeptin, pulsatile gonadorelin) to fertility-neutral (most GHS at moderate doses) to fertility-unknown (most research peptides) to potentially harmful during pregnancy (GLP-1 agonists in pregnancy based on animal data). The responsible approach is to plan peptide use around conception timelines, not the reverse.

FAQ

Can peptides help with male infertility?

Kisspeptin-10 and Gonadorelin can support male fertility by stimulating the HPG axis — increasing LH and FSH, which drive testosterone production and spermatogenesis. This is particularly relevant for men on TRT (which suppresses endogenous sperm production). Gonadorelin or hCG is commonly prescribed alongside TRT specifically to maintain testicular function and sperm production. For men with hypogonadotropic hypogonadism, pulsatile GnRH therapy is an established fertility treatment with strong clinical evidence.

Do I need to stop peptides before IVF?

Yes. Most reproductive endocrinologists recommend discontinuing all research peptides at least 1-3 months before IVF cycles. GLP-1 agonists (semaglutide) should be stopped at least 2 months before conception per FDA guidance due to animal teratogenicity data. The only peptides potentially continued during fertility treatment are those prescribed by the fertility specialist themselves (kisspeptin, GnRH analogs). The conservative approach — discontinuing everything without reproductive safety data — is the standard recommendation.

Can semaglutide affect fertility?

Semaglutide is not known to impair fertility in humans, but it must be discontinued before pregnancy due to animal data showing developmental toxicity. Some fertility specialists actually note that weight loss from GLP-1 agonists can improve fertility in overweight/obese women by restoring ovulation (excess body fat disrupts the HPG axis through aromatase-mediated estrogen excess). However, adequate contraception is required during semaglutide use, and a washout period of at least 2 months is recommended before attempting conception.

How long before trying to conceive should I stop peptides?

For women: discontinue all research peptides (BPC-157, TB-500, Melanotan II, etc.) at least 3 months before conception. Stop semaglutide at least 2 months before. Stop tirzepatide at least 1 month before. For men: discontinue research peptides at least 3 months before planned conception (one full spermatogenesis cycle is approximately 74 days). GH secretagogues at moderate doses are considered lower risk for men, but precautionary discontinuation is reasonable when reproductive safety data is absent.

Can BPC-157 affect pregnancy?

No reproductive toxicity data exists for BPC-157 in any species. Its pro-angiogenic mechanisms (VEGFR2 upregulation, NO system modulation) could theoretically affect implantation, placental development, or embryogenesis in ways that are completely unstudied. The precautionary principle demands discontinuation before planned conception for both partners. BPC-157 should absolutely not be used during pregnancy — the risk of unknown teratogenic effects outweighs any therapeutic benefit during a period when proven alternatives exist for most conditions BPC-157 addresses.